Bond signs $250,000 phase 1 agreement with top-five global pharmaceutical company

Our Bond, Inc. -26.24%

Our Bond, Inc.

OBAI

0.89

-26.24%

Our Bond, Inc. (NASDAQ: OBAI) said it signed a phase 1 commercial agreement worth about $250,000 with one of the world’s five largest pharmaceutical companies. The deal covers deployment of Bond’s AI-powered personal security platform for 5,000 employees in the United States and is expected to add about $250,000 in annual recurring revenue, with potential expansion that could lift cumulative contract value beyond $1 million over time.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG-17 Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602230837PRIMZONEFULLFEED9659139) on February 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.